Fang Jie, Hsu Betty Y L, MacMullen Courtney M, Poncz Mortimer, Smith Thomas J, Stanley Charles A
Division of Endocrinology, The Children's Hospital of Philadelphia, 34th Street & Civic Center Boulevard, Philadelphia, PA 19104, USA.
Biochem J. 2002 Apr 1;363(Pt 1):81-7. doi: 10.1042/0264-6021:3630081.
Glutamate dehydrogenase (GDH) catalyses the reversible oxidative deamination of l-glutamate to 2-oxoglutarate in the mitochondrial matrix. In mammals, this enzyme is highly regulated by allosteric effectors. The major allosteric activator and inhibitor are ADP and GTP, respectively; allosteric activation by leucine may play an important role in amino acid-stimulated insulin secretion. The physiological significance of this regulation has been highlighted by the identification of children with an unusual hyperinsulinism/hyperammonaemia syndrome associated with dominant mutations in GDH that cause a loss in GTP inhibition. In order to determine the effects of these mutations on the function of the human GDH homohexamer, we studied the expression, purification and characterization of two of these regulatory mutations (H454Y, which affects the putative GTP-binding site, and S448P, which affects the antenna region) and a mutation designed to alter the putative binding site for ADP (R463A). The sensitivity to GTP inhibition was impaired markedly in the purified H454Y (ED(50), 210 microM) and S448P (ED(50), 3.1 microM) human GDH mutants compared with the wild-type human GDH (ED(50), 42 nM) or GDH isolated from heterozygous patient cells (ED(50), 290 and 280 nM, respectively). Sensitivity to ADP or leucine stimulation was unaffected by these mutations, confirming that they interfere specifically with the inhibitory GTP-binding site. Conversely, the R463A mutation completely eliminated ADP activation of human GDH, but had little effect on either GTP inhibition or leucine activation. The effects of these three mutations on ATP regulation indicated that this nucleotide inhibits human GDH through binding of its triphosphate tail to the GTP site and, at higher concentrations, activates the enzyme through binding of the nucleotide to the ADP site. These data confirm the assignment of the GTP and ADP allosteric regulatory sites on GDH based on X-ray crystallography and provide insight into the structural mechanisms involved in positive and negative allosteric control and in inter-subunit co-operativity of human GDH.
谷氨酸脱氢酶(GDH)在线粒体基质中催化L-谷氨酸可逆氧化脱氨生成2-氧代戊二酸。在哺乳动物中,该酶受到变构效应物的高度调控。主要的变构激活剂和抑制剂分别是ADP和GTP;亮氨酸的变构激活可能在氨基酸刺激的胰岛素分泌中起重要作用。通过鉴定患有异常高胰岛素血症/高氨血症综合征的儿童,这种调控的生理意义得到了凸显,这些儿童与GDH中的显性突变相关,这些突变导致GTP抑制作用丧失。为了确定这些突变对人GDH同型六聚体功能的影响,我们研究了其中两个调控突变(影响假定GTP结合位点的H454Y和影响触角区域的S448P)以及一个旨在改变假定ADP结合位点的突变(R463A)的表达、纯化和特性。与野生型人GDH(ED50,42 nM)或从杂合患者细胞中分离的GDH(ED50分别为290和280 nM)相比,纯化的H454Y(ED50,210 μM)和S448P(ED50,3.1 μM)人GDH突变体对GTP抑制的敏感性明显受损。这些突变不影响对ADP或亮氨酸刺激的敏感性,证实它们特异性干扰抑制性GTP结合位点。相反,R463A突变完全消除了ADP对人GDH的激活作用,但对GTP抑制或亮氨酸激活几乎没有影响。这三个突变对ATP调控的影响表明,该核苷酸通过其三磷酸尾巴与GTP位点结合来抑制人GDH,而在较高浓度下,通过核苷酸与ADP位点结合来激活该酶。这些数据证实了基于X射线晶体学对GDH上GTP和ADP变构调节位点的定位,并深入了解了人GDH中正向和负向变构控制以及亚基间协同作用所涉及的结构机制。